EA201600316A2 - ANTITUBERCULOSIC VACCINE ON THE BASIS OF RECOMBINANT PROTEINS Ag85B, TB10.4, FLiC - Google Patents

ANTITUBERCULOSIC VACCINE ON THE BASIS OF RECOMBINANT PROTEINS Ag85B, TB10.4, FLiC

Info

Publication number
EA201600316A2
EA201600316A2 EA201600316A EA201600316A EA201600316A2 EA 201600316 A2 EA201600316 A2 EA 201600316A2 EA 201600316 A EA201600316 A EA 201600316A EA 201600316 A EA201600316 A EA 201600316A EA 201600316 A2 EA201600316 A2 EA 201600316A2
Authority
EA
Eurasian Patent Office
Prior art keywords
safe
excipient
create
vaccine
erudite
Prior art date
Application number
EA201600316A
Other languages
Russian (ru)
Other versions
EA031495B1 (en
EA201600316A3 (en
Inventor
Илья Владимирович ДУХОВЛИНОВ
Александр Леонидович КАДЫКОВ
Андрей Семенович СИМБИРЦЕВ
Екатерина Алексеевна ФЕДОРОВА
Original Assignee
Общество с ограниченной ответственностью "РД-БИОТЕХ"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "РД-БИОТЕХ" filed Critical Общество с ограниченной ответственностью "РД-БИОТЕХ"
Publication of EA201600316A2 publication Critical patent/EA201600316A2/en
Publication of EA201600316A3 publication Critical patent/EA201600316A3/en
Publication of EA031495B1 publication Critical patent/EA031495B1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к молекулярной биологии, биотехнологии, медицине. Предложена противотуберкулезная вакцина, содержащая рекомбинантные белки Ag85B и ТВ10.4 M.tuherculosis, а также рекомбинантный адъювант - флагеллин FliC Salmonella enterica serovar Typhimurium, а также фармацевтически приемлемый эксципиент, для решения острой задачи современности, заключающейся в создании безопасной при производстве и применении противотуберкулезной вакцины, имеющей эффективность, как минимум, сравнимую с таковой БЦЖ. Указанные свойства предложенной вакцины подтверждены примерами.The invention relates to molecular biology, biotechnology, medicine. An anti-tuberculosis vaccine containing recombinant proteins Ag85B and TB10.4 M.tuherculosis, as well as recombinant adjuvant - flagellin FliC Salmonella enterica serovar Typhimurium, as well as a pharmaceutically acceptable excipient, are proposed for solving the acute problem of modernity, which is to create a safe environment, to create a safe, erudite excipient for solving a modern problem, which is to create a safe, erudite excipient, to create a safe, modern, effective excipient to solve an acute problem of modernity that creates a safe, erudite excipient, which creates a safe, erudable excipient, which creates a safe, discharging antigen. with efficacy at least comparable to that of BCG. These properties of the proposed vaccine are confirmed by examples.

EA201600316A 2015-03-19 2016-05-05 ANTITUBERCULOSIS VACCINE BASED ON RECOMBINANT Ag85B, TB10.4, FliC PROTEINS EA031495B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015109715/15A RU2015109715A (en) 2015-03-19 2015-03-19 ANTITUBERCULOSIS VACCINE BASED ON RECOMBINANT PROTEINS Ag85B, TB10.4, FliC

Publications (3)

Publication Number Publication Date
EA201600316A2 true EA201600316A2 (en) 2016-10-31
EA201600316A3 EA201600316A3 (en) 2016-11-30
EA031495B1 EA031495B1 (en) 2019-01-31

Family

ID=53880100

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600316A EA031495B1 (en) 2015-03-19 2016-05-05 ANTITUBERCULOSIS VACCINE BASED ON RECOMBINANT Ag85B, TB10.4, FliC PROTEINS

Country Status (2)

Country Link
EA (1) EA031495B1 (en)
RU (1) RU2015109715A (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2300609B1 (en) * 2008-06-25 2013-11-20 INSERM - Institut National de la Santé et de la Recherche Médicale Novel immunoadjuvant flagellin-based compounds and use thereof
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
RU2524133C2 (en) * 2012-11-15 2014-07-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Escherichia coli BACTERIA STRAIN - PRODUCER OF RECOMBINANT FLAGELLIN

Also Published As

Publication number Publication date
EA031495B1 (en) 2019-01-31
EA201600316A3 (en) 2016-11-30
RU2015109715A (en) 2015-08-20

Similar Documents

Publication Publication Date Title
CY1124288T1 (en) CMV VACCINE
BR112016028816A8 (en) immunogenic combination, method of obtaining a specific immune response, use of an immunogenic combination, and, vaccination regimen for the prevention, reduction or treatment of respiratory syncytial virus infection
EA201890735A1 (en) Modulators of the cow protein of the hepatitis B virus
CY1119435T1 (en) PACKAGE FOR ANTI-ALPHA4VITA7
BR112018068748A2 (en) compound, pharmaceutical and vaccine composition, methods for inducing or promoting an immune response, for treating cancer, infectious diseases, immunological disorders and immunological diseases, and for treating or preventing a disease, and, using a compound
MX2018005569A (en) Vaccines against hepatitis b virus.
EA201791702A1 (en) THERAPEUTIC TOOLS ON THE BASIS OF GLYCANS AND RELATED METHODS
BR112016028288A2 (en) compound, pharmaceutical composition, methods for treating an individual with a disease or condition and for inhibiting kinase, and use of a compound.
BR112017008165A2 (en) single domain antibodies directed against intracellular antigens
BR112016028066A2 (en) vaccine composition; idessuis; ridessuis; antibody; parenteral composition; use of an idessuis or ridessuis protein; and host cell
EA201990071A1 (en) PEPTIDE VACCINE COMPOSITION
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
EA201591579A1 (en) METHODS OF TREATMENT OF CROWN DISEASE WITH ANTI-IL-23 ANTIBODIES
BR112018072545A2 (en) arginase inhibitors and their therapeutic applications
EA201790239A1 (en) MOLECULE CARRIER FOR ANTIGENS
CL2018000565A1 (en) Compounds derived from pyridinone dicarboxamide, bromodomain inhibitors; pharmaceutical composition; pharmaceutical combination; Useful in the treatment of autoimmune, inflammatory, viral and cancer diseases, among others.
CY1121554T1 (en) PRODUCER OF PYRANOCHROMENYL-PHENOLIS, AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME OR INFLAMMATORY DISEASE
BR112015030229A8 (en) VIRUS-LIKE PARTICLE COMPRISING A POLYPEPTIDE AND A MALARIA ANTIGEN, VECTOR, PHARMACEUTICAL AND VACCINE COMPOSITIONS, AS WELL AS ISOLATED NUCLEIC ACID MOLECULE
BR112015025748A2 (en) DNA construction for immunomodulation, pharmaceutical composition, vaccine, and use of a DNA construction
BR112016012599A2 (en) composition and method for treating or preventing a staphylococcus aureus infection
PH12016501988A1 (en) Antibacterial compounds
BR112017004796A2 (en) method for using hydroxamic acid derivatives and antibacterial substance in combination
EA201691860A1 (en) PEPTIDE MEDICINE AS A DRY POWDER
EA201990451A1 (en) COMPOSITION OF MULTI-VALENT PNEUMO-COCK CAPSULE POLYSACCHARIDE COMPOUNDS WITH PROTEIN-CARRIER AND ITS APPLICATION
UY36217A (en) PIRIDONA SUBSTITUTE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ